Hyalescent Ventures

Hyalescent Ventures is a St. Louis-based biotechnology company dedicated to discovering novel therapeutic targets within the "dark proteome." Founded by Dr. Michael Kinch, a renowned expert in drug development and former Associate Vice Chancellor at Washington University, the company leverages a proprietary data-driven platform to identify biological pathways that have been historically overlooked by the pharmaceutical industry. The firm's primary focus is on developing first-in-class treatments for oncology and infectious diseases. By combining historical drug development data with modern molecular insights, Hyalescent Ventures aims to streamline the path from discovery to clinical application. The company operates as a discovery-stage entity, utilizing its platform to build a pipeline of candidates targeting previously "undruggable" proteins.